# Efficacy of Short Term Dabigatran Etexilate Followed by Aspirin Monotherapy After LAA (Left Atrial Appendage) Device Closure (the DEA-LAA Study).

Study · id `cardio:ct-nct03539055` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03539055](<https://clinicaltrials.gov/study/NCT03539055>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03539055

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

## Technical summary

Registry record NCT03539055. Allocation not applicable; no masking; primary purpose prevention. Start 2018-09-01 (actual); primary completion 2023-12-31 (actual). Results posted on 2025-06-10.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 100 participants (enrolled count; ClinicalTrials.gov record NCT03539055, source copy `cardio:ctgov-nct03539055-2025-06-10`, retrieved 2026-10-26)
- Started: 2018-09-01 (actual) (ClinicalTrials.gov record NCT03539055, source copy `cardio:ctgov-nct03539055-2025-06-10`, retrieved 2026-10-26)
- Primary completion: 2023-12-31 (actual) (ClinicalTrials.gov record NCT03539055, source copy `cardio:ctgov-nct03539055-2025-06-10`, retrieved 2026-10-26)
- Completion: 2024-02-29 (actual) (ClinicalTrials.gov record NCT03539055, source copy `cardio:ctgov-nct03539055-2025-06-10`, retrieved 2026-10-26)
- Results first posted: 2025-06-10 (ClinicalTrials.gov record NCT03539055, source copy `cardio:ctgov-nct03539055-2025-06-10`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT03539055, source copy `cardio:ctgov-nct03539055-2025-06-10`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03539055-2025-06-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy of Short Term Dabigatran Etexilate Followed by Aspirin Monotherapy After LAA (Left Atrial Appendage) Device Closure (the DEA-LAA Study).
- Acronym: DEA-LAA
- Condition: Atrial Fibrillation
- Condition: Device Related Thrombus
- Condition: Left Atrial Appendage Thrombosis
- Condition: Watchman LAA Closure Device
- Intervention (Drug): Dabigatran Etexilate Oral Capsule
- Lead sponsor: Vanderbilt University Medical Center
- Lead sponsor class: OTHER
- Collaborator: Boehringer Ingelheim
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Vanderbilt University Medical Center (`cardio:org-vanderbilt-university-medical-center`)
- Registry lists this organization as a collaborator: Boehringer Ingelheim (`cardio:boehringer-ingelheim`)

## Provenance

Content hash: bda88d59df2ade29649db2dadbe9b6e00cc0838d4f45bfeb56d37d882433b230
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
